Combining all-trans retinoic acid (ATRA) with arsenic trioxide (ATO) and idarubicin significantly improved event-free survival (EFS) compared with the standard treatment of ATRA and ...

Acute promyelocytic leukaemia (APL) represents a unique and once highly fatal subtype of acute myeloid leukaemia that is now considered among the most curable forms of haematological malignancies.

Quetzal Therapeutics, a biopharmaceutical company focused on developing treatments for rare diseases, announced that the U.S.

The Food and Drug Administration (FDA) has granted Fast Track designation to QTX-2101, an oral formulation of arsenic trioxide, for the treatment of acute promyelocytic leukemia (APL), an aggressive ...

CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics , a biopharmaceutical company specializing in developing transformative treatments for rare diseases, announced the initiation of a ...

Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have invented an oral formulation of arsenic trioxide (Oral-ATO; ARSENOL) for the treatment of acute promyelocytic ...

Findings from the international study involving about 220 newly diagnosed and relapse patient samples pave the way for development of new therapies A study led by a team of scientists from the Cancer ...

Researchers at Zhejiang University School of Medicine have identified a single point mutation in the normal PML gene that can block the effect of arsenic trioxide, a frontline drug for acute ...